MANKIND PHARMA
|
The Current P/E Ratio of MANKIND PHARMA is 46.42.
| Share Price | ₹2,020.3 | Mar 25,2026 |
| Market Cap | ₹83,395.9 Cr | |
| Earnings-TTM | ₹1,796.7 Cr | TTM-Consolidated Results |
| Price/Earnings | 46.42x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of MANKIND PHARMA
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹83,395.9 Cr] as on Mar 25,2026
(/) Earnings [ ₹1,796.7 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 46.42x ]
Thus, for MANKIND PHARMA , the investors are currently willing to pay 46.42 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of MANKIND PHARMA !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of MANKIND PHARMA over the last five years.
Historical PE (Price/Earnings) ratio chart of MANKIND PHARMA
PE Ratio Performance Analysis for MANKIND PHARMA
- MANKIND PHARMA 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 19.67x.
- MANKIND PHARMA 's operated at median p/e ratio of 0x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, MANKIND PHARMA 's p/e ratio peaked in Mar2025 at 50.22x.
- MANKIND PHARMA 's p/e ratio hit its five-year low in Mar2023 of 0x.
How does MANKIND PHARMA 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| MANKIND PHARMA | 1,796.65 | 46.42 | 83,395.9 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,001.40 | 39.14 | 430,645.0 |
| DIVIS LABORATORIES LTD | 2,479.00 | 64.39 | 159,625.0 |
| CIPLA LTD | 4,544.70 | 22.11 | 100,480.0 |
| TORRENT PHARMACEUTICALS LTD | 2,272.00 | 64.00 | 145,415.0 |
| DR REDDYS LABORATORIES LTD | 5,508.70 | 19.73 | 108,664.0 |
| ZYDUS LIFESCIENCES LTD | 4,933.90 | 18.43 | 90,923.3 |
| LUPIN LTD | 4,669.18 | 22.98 | 107,321.0 |
| AUROBINDO PHARMA LTD | 3,513.20 | 21.62 | 75,951.4 |
| ABBOTT INDIA LTD | 1,524.13 | 36.80 | 56,092.5 |
| ALKEM LABORATORIES LTD | 2,424.46 | 26.80 | 64,983.6 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs MANKIND PHARMA 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 18.43x |
| Max industry PE | 64.39x |
| Median industry PE | 26.80x |
| Average industry PE | 34.77x |
You may also like the below Video Courses